Journal of Nanomedicine & Biotherapeutic Discovery
Open Access
ISSN: 2155-983X
ISSN: 2155-983X
Department of Research and Development, Vidac Pharma Ltd, Rehovot, Israel
Research Article
A novel chemical entity, that reverses Warburg metabolism by disrupting VDAC1/HK2 interaction through ?Toposteric Effect? in Cancer
Author(s): Max Herzberg, Oren M. Becker, Vered Behar, Reut Yosef, Eyal Dor-On, Hadas Pahima, Veronique de Conto, Nathalie Maubon and Yuval Sagiv*
Background: Acidic pH and low oxygen levels due to the Warburg effect have been shown to impart resistance to certain anti-cancer therapies for solid tumors, such as radiation and a variety of chemotherapeutic drugs. Cancer immunotherapy represents one of the most exciting advancements in recent cancer therapy. However, despite these achievements, the numbers of patients with effective cure are very low for patients with solid tumors. Recent studies pointed out that the main cause for this low efficiency is the Tumor Microenvironment (TME), with metabolic changes, and immune evasion that renders solid tumor eradication a real challenge. Drugs targeting the inhibitory TME are urgently needed in combination with immunotherapy, as well as other conventional therapies like chemotherapy and cancer targeted growth blockers. Methods: In this study we used an inhibitor of Hexokinase-2 binding.. View More»
DOI:
10.35248/2155-983X-25.15.301